Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Park, Byung Joon ^a   Cha, Mee Kyung ^a   Kim, Il Han ^a  

^a PaiChai University   (South Korea)

Author keywords

Breast cancer; Cancer antigen 15 3 (CA15 3); Carcinoembryonic antigen (CEA); Companion marker; Diagnosis; Reactive oxygen species; Thioredoxin 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MUCIN 1; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; AGING; AREA UNDER THE CURVE; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; AREA UNDER CURVE; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MUCIN-1; REACTIVE OXYGEN SPECIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891544665     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-7     Document Type: Article

References (29)

1. Requirement for generation of H§ssub§2§esub§O§ ssub§2§esub§ for platelet-derived growth factor signal transduction. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T, Science 1995 270 296 299 10.1126/science.270.5234.296 7569979
2. Oxygen radicals and signaling. Finkel T, Curr Opin Cell Biol 1998 10 248 253 10.1016/S0955-0674(98)80147-6 9561849 (Pubitemid 28174767)
3. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG, J Biol Chem 1998 273 6297 6302 10.1074/jbc.273.11.6297 9497357 (Pubitemid 28144719)
4. Cloning and sequencing of thiol-specific antioxidant from mammalian brain, alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG, Proc Natl Acad Sci U S A 1994 91 7017 7021 10.1073/pnas.91.15.7017 8041738 (Pubitemid 24226793)
5. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Schumacker PT, Cancer Cell 2006 10 175 176 10.1016/j.ccr.2006.08.015 16959608 (Pubitemid 44311072)
6. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P, Cancer Cell 2006 10 241 252 10.1016/j.ccr.2006.08.009 16959615 (Pubitemid 44311067)
7. Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Mitsui A, Hirakawa T, Yodoi J, Biochem Biophys Res Commun 1992 186 1220 1226 10.1016/S0006-291X(05)81536-0 1510657 (Pubitemid 23189454)
8. Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. Ohira A, Honda O, Gauntt CD, Yamamoto M, Hori K, Masutani H, Yodoi J, Honda Y, Lab Invest 1994 70 279 285 8139268
9. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Nakamura H, Matsuda M, Furuke K, Kitaoka Y, Iwata S, Toda K, Inamoto T, Yamaoka Y, Ozawa K, Yodoi J, Immunol Lett 1994 42 75 80 10.1016/0165-2478(94) 90038-8 7829134 (Pubitemid 24305198)
10. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): Protective effect of human thioredoxin against CDDP-induced cytotoxicity. Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama Taniguchi A, Takabayashi A, Yodoi J, J Clin Invest 1996 97 2268 2276 10.1172/JCI118668 8636406
11. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Schenk H, Klein M, Erdbrugger W, Droge W, Schulze OK, Proc Natl Acad Sci USA 1994 91 1672 1676 10.1073/pnas.91.5.1672 8127864 (Pubitemid 24080267)
12. Thioredoxin: A redox-regulating cellular cofactor for glucocorticoid hormone action: crosstalk between endocrine control of stress response and cellular antioxidant defense system. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, Umesono K, Makino I, Tanaka H, J Clin Invest 1995 98 2469 2477 (Pubitemid 26415067)
13. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. Ueno M, Masutani H, Arai AJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka J, Yodoi J, Nikaido T, J Biol Chem 1999 274 35809 35815 10.1074/jbc.274.50.35809 10585464 (Pubitemid 129512885)
14. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Hayashi S, Hajiro NK, Makino Y, Eguchi H, Yodoi Y, Tanaka H, Nucleic Acids Res 1997 25 4035 4040 10.1093/nar/25.20.4035 9321654 (Pubitemid 27443331)
15. The thioredoxin system in cancer. Arner ES, Holmgren A, Semin Cancer Biol 2006 16 420 426 10.1016/j.semcancer.2006.10.009 17092741 (Pubitemid 44780139)
16. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Matsutani Y, Yamauchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K, Nakamura H, Kato H, Kodama H, Inamoto T, Yodoi J, Yamaoka Y, Clin Cancer Res 2001 7 3430 3436 11705859 (Pubitemid 33069977)
17. Expression and growth-promoting effect of adult T-cell leukemia-derived factor: a human thioredoxin homologue in hepatocellular carcinoma. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K, Yodoi Y, Cancer 1992 69 2091 2097 10.1002/1097-0142(19920415)69:8<2091::AID- CNCR2820690814>3.0.CO;2-X 1311982
18. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, Yodoi Y, Cancer 1991 68 1583 1591 10.1002/1097-0142(19911001)68:7<1583::AID- CNCR2820680720>3.0.CO;2-N 1654198
19. Biochemical and topological analysis of adult T-cell leukaemia-derived factor, homologous to thioredoxin, in the pregnant human uterus. Kobayashi F, Sagawa N, Nanbu Y, Kitaoka Y, Mori T, Fujii S, Nakamura H, Masutani H, Yodoi Y, Hum Reprod 1995 10 1603 1608 10.1093/HUMREP/10.6.1603 7593543
20. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Allemani C, Sant M, Weir HK, Richardson LC, et al. Int J Cancer 2013 132 1170 1181 10.1002/ijc.27725 22815141
21. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. Cha MK, Suh KH, Kim IH, Exp Clin Cancer Res 2009 28 93 doi: 10.1186/1756-9966-28-93 10.1186/1756-9966-28-93
22. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, J Clin Oncol 2007 25 5287 5312 10.1200/JCO.2007.14.2364 17954709 (Pubitemid 350232263)
23. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. Gold P, Freedman SO, J Exp Med 1965 121 439 462 10.1084/jem.121.3.439 14270243
24. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Hammarström S, Semin Cancer Biol 1999 9 67 81 10.1006/scbi.1998.0119 10202129 (Pubitemid 29265523)
25. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA, Ann Clin Biochem 1998 35 99 103 9463746 (Pubitemid 28043632)
26. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K, J Biol Chem 2008 283 15647 15655 10.1074/jbc.M800543200 18375392
27. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, et al. Eur J Cancer 2003 39 718 727 10.1016/S0959-8049(02)00811-0 12651195 (Pubitemid 36315986)
28. The activity of class I, II, III and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in breast cancer. Jelski W, Chrostek L, Szmitkowski M, Markiewicz W, Clin Exp Med 2006 6 89 93 10.1007/s10238-006-0101-z 16820997
29. Activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with breast cancer. Jelski W, Chrostek L, Markiewicz W, Szmitkowski M, J Clin Lab Anal 2006 20 105 108 10.1002/jcla.20109 16721836 (Pubitemid 43830451)